The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Impax Laboratories beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.
Margins dropped across the board.
Impax Laboratories logged revenue of $141.1 million. The 13 analysts polled by S&P Capital IQ expected net sales of $126.6 million on the same basis. GAAP reported sales were 11% lower than the prior-year quarter's $158.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.30. The 13 earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. Non-GAAP EPS of $0.30 for Q4 were 17% lower than the prior-year quarter's $0.36 per share. GAAP EPS of $0.07 for Q4 were 78% lower than the prior-year quarter's $0.32 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 45.5%, 330 basis points worse than the prior-year quarter. Operating margin was 5.7%, much worse than the prior-year quarter. Net margin was 3.4%, much worse than the prior-year quarter.
Next quarter's average estimate for revenue is $142.9 million. On the bottom line, the average EPS estimate is $0.22.
Next year's average estimate for revenue is $569.1 million. The average EPS estimate is $0.73.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 167 members out of 180 rating the stock outperform, and 13 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 52 give Impax Laboratories a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $25.44.
- Add Impax Laboratories to My Watchlist.